RELMADA THERAPEUTICS INC (RLMD)
US75955J4022 - Common Stock
ChartMill assigns a Buy % Consensus number of 48% to RLMD. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 0.88. This target is 88.05% above the current price.
RLMD was analyzed by 8 analysts. The buy percentage consensus is at 48. So analysts seem to be rather neutral about RLMD.
In the last month the buy percentage fell by 34 points. So the trust of analysts is decreasing.
RLMD was analyzed by 8 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-12-05 | Mizuho | Downgrade | Outperform -> Neutral |
| 2024-12-04 | Leerink Partners | Downgrade | Outperform -> Market Perform |
| 2024-09-17 | Jefferies | Upgrade | Hold -> Buy |
| 2024-06-05 | Goldman Sachs | Downgrade | Neutral -> Sell |
| 2023-06-15 | Mizuho | Reiterate | Buy -> Buy |
| 2023-01-23 | SVB Leerink | Maintains | Outperform |
| 2022-10-14 | Guggenheim | Downgrade | Buy -> Neutral |
| 2022-10-14 | Goldman Sachs | Downgrade | Buy -> Neutral |
| 2022-10-13 | Oppenheimer | Downgrade | Outperform -> Perform |
| 2022-09-23 | Goldman Sachs | Maintains | Buy |
| 2022-09-06 | Guggenheim | Maintains | Buy |
| 2022-05-09 | Oppenheimer | Maintains | Outperform |
| 2021-12-20 | SVB Leerink | Maintains | Outperform |
| 2021-11-18 | Mizuho | Initiate | Buy |